

David S Hong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1782987/publications.pdf>

Version: 2024-02-01

209
papers

17,649
citations

25014

57
h-index

16164

124
g-index

213
all docs

213
docs citations

213
times ranked

23811
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e16-e24.	0.9	1
2	Investigating the natural history and prognostic nature of NTRK gene fusions in solid tumors. <i>Investigational New Drugs</i> , 2022, 40, 157-162.	1.2	2
3	NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. <i>British Journal of Cancer</i> , 2022, 126, 514-520.	2.9	19
4	Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 479-488.	3.2	16
5	Factors associated with relapse-free survival after neoadjuvant chemotherapy for breast cancer at a safety net medical center. <i>American Journal of Surgery</i> , 2022, 223, 539-542.	0.9	2
6	A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100262.	0.6	7
7	Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib. <i>Cancer Genetics</i> , 2022, 260-261, 46-52.	0.2	5
8	Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreak100): a prespecified analysis of a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 115-124.	5.1	147
9	Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. , 2022, 10, e003776.		79
10	Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. <i>Frontiers in Oncology</i> , 2022, 12, 818679.	1.3	8
11	Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2022, 165, 664-670.	0.6	7
12	Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. <i>Oncologist</i> , 2022, , .	1.9	18
13	A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors. <i>Frontiers in Immunology</i> , 2022, 13, 845417.	2.2	3
14	Basket Trials: Review of Current Practice and Innovations for Future Trials. <i>Journal of Clinical Oncology</i> , 2022, 40, 3520-3528.	0.8	10
15	Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. , 2022, 10, e004822.		11
16	Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. <i>JCO Precision Oncology</i> , 2022, , .	1.5	15
17	Therapeutics Targeting Mutant KRAS. <i>Annual Review of Medicine</i> , 2021, 72, 349-364.	5.0	41
18	First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. <i>Cancer Discovery</i> , 2021, 11, 80-91.	7.7	148

#	ARTICLE	IF	CITATIONS
19	Intratumoral Injection of <i>Clostridium novyi</i> -NT Spores in Patients with Treatment-refractory Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 96-106.	3.2	59
20	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021, 19, 395-402.	1.5	7
21	Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with <i>BRAF</i> -mutated advanced cancers. <i>Cancer</i> , 2021, 127, 391-402.	2.0	6
22	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor ⁺ positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1247-1255.	3.2	5
23	Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. <i>Clinical Cancer Research</i> , 2021, 27, 1864-1874.	3.2	20
24	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO [®] Friends of Cancer Research Prior Therapies Work Group. <i>Clinical Cancer Research</i> , 2021, 27, 2408-2415.	3.2	14
25	Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in <i>BRAF</i> -Mutant Metastatic Colorectal Cancer (SWOG S1406). <i>Journal of Clinical Oncology</i> , 2021, 39, 285-294.	0.8	169
26	Accreditation Program for Excellence (APEX): A Catalyst for Quality Improvement. <i>Practical Radiation Oncology</i> , 2021, 11, 101-107.	1.1	5
27	A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 3050-3060.	3.2	24
28	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. <i>Npj Precision Oncology</i> , 2021, 5, 21.	2.3	12
29	Mechanisms of Resistance to <i>KRAS</i> G12C-Targeted Therapy. <i>Cancer Discovery</i> , 2021, 11, 1345-1352.	7.7	60
30	Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. <i>Current Problems in Cancer</i> , 2021, 45, 100734.	1.0	9
31	Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4974-4982.	3.2	30
32	Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> ^{G12C} -Mutant Colorectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 613-621.	1.5	31
33	Overview of Ocular Side Effects of Selinexor. <i>Oncologist</i> , 2021, 26, 619-623.	1.9	5
34	Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. <i>Oncologist</i> , 2021, 26, 588-596.	1.9	42
35	Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 428-440.	1.3	13
36	Moving Beyond 3+3: The Future of Clinical Trial Design. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e133-e144.	1.8	33

#	ARTICLE	IF	CITATIONS
37	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i> . <i>Clinical Cancer Research</i> , 2021, 27, 5236-5247.	3.2	74
38	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5781-5792.	3.2	30
39	A phase I study of ixazomib and erlotinib in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2021, , 1.	1.2	0
40	A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. <i>Targeted Oncology</i> , 2021, 16, 569-589.	1.7	10
41	High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. <i>Radiotherapy and Oncology</i> , 2021, 162, 60-67.	0.3	45
42	A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden. <i>Nature Biomedical Engineering</i> , 2021, 5, 297-308.	11.6	28
43	Engineered T-cell Receptor T Cells for Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 1252-1261.	1.6	16
44	Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. <i>ELife</i> , 2021, 10, .	2.8	8
45	Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring <i>MET</i> Exon 14 Skipping. <i>JCO Precision Oncology</i> , 2021, 5, 1802-1812.	1.5	9
46	A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 460-467.	1.9	60
47	Factors affecting symptom presentation in an early-phase clinical trials clinic patient population. <i>Investigational New Drugs</i> , 2020, 38, 1166-1174.	1.2	1
48	Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1220-1228.	3.2	77
49	Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. <i>International Journal of Cancer</i> , 2020, 146, 3450-3460.	2.3	14
50	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 5579-5587.	3.2	16
51	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. <i>ESMO Open</i> , 2020, 5, e001073.	2.0	1
52	Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. , 2020, 8, e000537.		105
53	Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials. <i>British Journal of Cancer</i> , 2020, 123, 1496-1501.	2.9	35
54	KRAS ^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020, 383, 1207-1217.	13.9	1,049

#	ARTICLE	IF	CITATIONS
55	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. <i>Cancer Immunology Research</i> , 2020, 8, 1365-1380.	1.6	37
56	Phase I Study of P-cadherin- α -targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5830-5842.	3.2	17
57	Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. <i>Science Advances</i> , 2020, 6, eaay6298.	4.7	41
58	Specific learning disorders in sex chromosome aneuploidies: Neural circuits of literacy and mathematics. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2020, 184, 518-530.	0.7	6
59	Histology-agnostic drug development α considering issues beyond the tissue. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 555-568.	12.5	60
60	Dyslexia in Pediatrics: Simple Practices to Tackle a Complex Issue. <i>Pediatrics</i> , 2020, 146, e20201470.	1.0	2
61	First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE ₂ -receptor E-type 4 (EP4), in patients with advanced cancers. , 2020, 8, e000222.		34
62	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1924-1931.	3.2	50
63	Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1165-1172.	1.9	15
64	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 1237-1246.	3.2	61
65	Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. <i>Clinical Cancer Research</i> , 2020, 26, 4531-4541.	3.2	46
66	Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1759-1769.	2.0	9
67	Molecular Imaging with α -deoxy- α [(18)F]-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study. <i>Diagnostics</i> , 2020, 10, 125.	1.3	5
68	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology, The</i> , 2020, 21, 531-540.	5.1	608
69	Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 122, 1630-1637.	2.9	472
70	Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 102-102.	0.8	35
71	Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 824-824.	0.8	16
72	Considerations for the Attribution and Management of Toxicities in Phase I Clinical Trials. , 2020, , 109-118.		1

#	ARTICLE	IF	CITATIONS
73	379â€¦Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8Î± co-receptor. , 2020, , .		5
74	387â€¦A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies. , 2020, , .		4
75	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature, 2019, 575, 217-223.	13.7	1,375
76	Firstâ€¦inâ€¦human, phase I study of PFâ€¦06647263, an antiâ€¦FNA4 calicheamicin antibodyâ€¦drug conjugate, in patients with advanced solid tumors. International Journal of Cancer, 2019, 145, 1798-1808.	2.3	34
77	A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. Oncology, 2019, 97, 102-111.	0.9	67
78	Deep Learningâ€¦Assisted Diagnosis of Cerebral Aneurysms Using the HeadXNet Model. JAMA Network Open, 2019, 2, e195600.	2.8	163
79	Improving attribution of adverse events in oncology clinical trials. Cancer Treatment Reviews, 2019, 76, 33-40.	3.4	19
80	Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1â€¦2 trial. Lancet Oncology, The, 2019, 20, 383-393.	5.1	131
81	Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clinical Cancer Research, 2019, 25, 3802-3810.	3.2	42
82	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiationâ€¦Related Abscopal Responses. Cancer Immunology Research, 2019, 7, 1903-1909.	1.6	86
83	Basket Designs: Statistical Considerations for Oncology Trials. JCO Precision Oncology, 2019, 3, 1-9.	1.5	11
84	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. Journal of the National Cancer Institute, 2019, 111, 118-128.	3.0	49
85	Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2019, 25, 2403-2413.	3.2	40
86	Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). , 2019, , .		7
87	Phase I study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule <i>KRAS^{G12C}</i> inhibitor, in advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 3003-3003.	0.8	145
88	A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 3091-3091.	0.8	4
89	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. Journal of Medical Internet Research, 2019, 21, e10348.	2.1	13
90	Efficacy of Larotrectinib in<i>TRK</i>Fusionâ€¦Positive Cancers in Adults and Children. New England Journal of Medicine, 2018, 378, 731-739.	13.9	2,036

#	ARTICLE	IF	CITATIONS
91	Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3263-3272.	3.2	61
92	Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway. <i>Clinical Cancer Research</i> , 2018, 24, 1138-1151.	3.2	63
93	Untying the gordian knot of targeting MET in cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 95-103.	3.4	18
94	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. <i>British Journal of Cancer</i> , 2018, 118, 1419-1424.	2.9	7
95	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 181-188.	3.2	127
96	Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. <i>Investigational New Drugs</i> , 2018, 36, 416-423.	1.2	17
97	Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-14.	1.0	5
98	Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in <i>KIT</i> -Mutant Melanoma. <i>JCO Precision Oncology</i> , 2018, 2018, 1-8.	1.5	13
99	RADI-03. ASL PERFUSION IMAGING OF THE FRONTAL LOBES PREDICTS THE OCCURRENCE AND RESOLUTION OF POSTERIOR FOSSA SYNDROME. <i>Neuro-Oncology</i> , 2018, 20, i170-i170.	0.6	1
100	STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. , 2018, 6, 119.		165
101	A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 407-418.	1.1	46
102	Emerging Targeted Therapy for Tumors with <i>NTRK</i> Fusion Proteins. <i>Clinical Cancer Research</i> , 2018, 24, 5807-5814.	3.2	119
103	Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 3845-3856.	3.2	35
104	A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11514-11514.	0.8	30
105	Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3056-3056.	0.8	7
106	Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. <i>Clinical Cancer Research</i> , 2017, 23, 1407-1413.	3.2	11
107	Targeting TRK family proteins in cancer. , 2017, 173, 58-66.		217
108	Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. <i>Clinical Cancer Research</i> , 2017, 23, 1414-1421.	3.2	29

#	ARTICLE	IF	CITATIONS
109	Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs. <i>Clinical Cancer Research</i> , 2017, 23, 4020-4026.	3.2	14
110	Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers. <i>Radiology</i> , 2017, 283, 314-340.	3.6	19
111	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5648-5656.	3.2	50
112	Targeting <i>BRAF</i> -Mutant Colorectal Cancer: Progress in Combination Strategies. <i>Cancer Discovery</i> , 2017, 7, 558-560.	7.7	25
113	Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 180-188.	1.2	647
114	Phase I Trial: SABR and Ipilimumab Response. <i>Clinical Cancer Research</i> , 2017, 23, 321-321.	3.2	1
115	Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	16
116	Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. <i>Clinical Cancer Research</i> , 2017, 23, 4155-4162.	3.2	4
117	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. <i>Scientific Reports</i> , 2017, 7, 15963.	1.6	21
118	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. <i>Clinical Cancer Research</i> , 2017, 23, 1388-1396.	3.2	261
119	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. , 2017, 5, 100.		114
120	Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. <i>Oncotarget</i> , 2017, 8, 39254-39267.	0.8	62
121	Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2017, 35, 1304-1311.	0.8	82
122	Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. <i>Oncoscience</i> , 2017, 4, 47-56.	0.9	21
123	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a <i>de novo</i> phenomenon. <i>Oncotarget</i> , 2016, 7, 54627-54631.	0.8	53
124	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. <i>Scientific Reports</i> , 2016, 6, 35448.	1.6	12
125	Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. <i>ESMO Open</i> , 2016, 1, e000055.	2.0	28
126	cMET Exon 14 Skipping: From the Structure to the Clinic. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1423-1432.	0.5	51

#	ARTICLE	IF	CITATIONS
127	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1764-1771.	0.8	149
128	RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. <i>Cancer Treatment Reviews</i> , 2016, 50, 35-47.	3.4	128
129	<i>TP53</i> Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2475-2485.	1.9	73
130	Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. <i>Cancer</i> , 2016, 122, 3401-3409.	2.0	50
131	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. <i>Cancer Discovery</i> , 2016, 6, 1352-1365.	7.7	192
132	FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. <i>Journal of Translational Medicine</i> , 2016, 14, 339.	1.8	167
133	<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1397-1404.	1.9	78
134	Exosome-mediated drug resistance in cancer: the near future is here. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 320-322.	1.4	41
135	Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. <i>Oncotarget</i> , 2016, 7, 64421-64430.	0.8	17
136	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. <i>Oncotarget</i> , 2016, 7, 67521-67531.	0.8	44
137	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. <i>Oncotarget</i> , 2015, 6, 12809-12821.	0.8	86
138	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 215-224.	1.2	8
139	Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 4801-4810.	3.2	63
140	Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2015, 33, 621-631.	1.2	63
141	Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. <i>BMC Cancer</i> , 2015, 15, 61.	1.1	25
142	A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	168
143	Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv253.	3.0	139
144	Strategies for combining immunotherapy with radiation for anticancer therapy. <i>Immunotherapy</i> , 2015, 7, 967-980.	1.0	83

#	ARTICLE	IF	CITATIONS
145	AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer. <i>Science Translational Medicine</i> , 2015, 7, 314ra185.	5.8	352
146	Abstract C43: Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors. <i>Molecular Cancer Therapeutics</i> , 2015, 14, C43-C43.	1.9	15
147	A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. <i>Oncotarget</i> , 2015, 6, 18693-18706.	0.8	24
148	<i>BRAF</i> mutation testing with a rapid, fully integrated molecular diagnostics system. <i>Oncotarget</i> , 2015, 6, 26886-26894.	0.8	45
149	Targeting translation initiation in breast cancer. <i>Translation</i> , 2014, 2, e28968.	2.9	1
150	MET in ovarian cancer: Metastasis and resistance?. <i>Cell Cycle</i> , 2014, 13, 1220-1221.	1.3	6
151	Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs. <i>Clinical Cancer Research</i> , 2014, 20, 281-288.	3.2	46
152	Analysis of 1,115 Patients Tested for <i>MET</i> Amplification and Therapy Response in the MD Anderson Phase I Clinic. <i>Clinical Cancer Research</i> , 2014, 20, 6336-6345.	3.2	70
153	Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic. <i>Clinical Cancer Research</i> , 2014, 20, 5956-5963.	3.2	10
154	Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. <i>International Journal of Dermatology</i> , 2014, 53, 376-384.	0.5	62
155	Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?. <i>Cancer Immunology Research</i> , 2014, 2, 831-838.	1.6	270
156	STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia. <i>Oncologist</i> , 2014, 19, 536-544.	1.9	55
157	Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. <i>Cancer</i> , 2014, 120, 2164-2173.	2.0	27
158	MABp1, a first-in-class true human antibody targeting interleukin-1 \pm in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. <i>Lancet Oncology</i> , The, 2014, 15, 656-666.	5.1	178
159	A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 167-177.e2.	0.9	21
160	First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2508-2508.	0.8	19
161	FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. <i>PLoS ONE</i> , 2014, 9, e89388.	1.1	50
162	Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience. <i>Oncoscience</i> , 2014, 1, 522-530.	0.9	7

#	ARTICLE	IF	CITATIONS
163	A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. <i>Oncotarget</i> , 2014, 5, 11154-11167.	0.8	14
164	Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 963-970.	1.2	8
165	A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 918-926.	1.2	26
166	<i>PIK3CA</i> Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials. <i>Cancer Research</i> , 2013, 73, 276-284.	0.4	262
167	A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 955-963.	1.1	13
168	Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions. <i>Cancer Treatment Reviews</i> , 2013, 39, 375-387.	3.4	217
169	Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 4824-4831.	3.2	20
170	Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and <i>PIK3CA</i> Mutations. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2857-2863.	1.9	42
171	Merkel Cell Polyomavirus and HPV-17 Associated With Cutaneous Squamous Cell Carcinoma Arising in a Patient With Melanoma Treated With the BRAF Inhibitor Dabrafenib. <i>JAMA Dermatology</i> , 2013, 149, 322.	2.0	32
172	P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy. <i>Oncotarget</i> , 2013, 4, 705-714.	0.8	96
173	Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience. <i>Clinical Cancer Research</i> , 2012, 18, 2922-2929.	3.2	78
174	Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. <i>Clinical Cancer Research</i> , 2012, 18, 6373-6383.	3.2	458
175	BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency. <i>Clinical Cancer Research</i> , 2012, 18, 2326-2335.	3.2	109
176	A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas. <i>Clinical Cancer Research</i> , 2012, 18, 3396-3406.	3.2	188
177	Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: The MD Anderson Cancer Center Experience. <i>Clinical Colorectal Cancer</i> , 2012, 11, 297-303.	1.0	6
178	Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. <i>Cancer</i> , 2012, 118, 1422-1428.	2.0	88
179	Another Window of Opportunity. <i>Science Translational Medicine</i> , 2012, 4, .	5.8	0
180	The Mutation That Broke the Cell's Back. <i>Science Translational Medicine</i> , 2012, 4, .	5.8	0

#	ARTICLE	IF	CITATIONS
181	PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers. PLoS ONE, 2011, 6, e22769.	1.1	174
182	Prevalence of complementary medicine use in a phase 1 clinical trials program. Cancer, 2011, 117, 5142-5150.	2.0	53
183	Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Maligancies. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 997-1005.	1.8	100
184	Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer. Journal of Clinical Oncology, 2011, 29, 2660-2666.	0.8	504
185	A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer. Clinical Cancer Research, 2011, 17, 6582-6591.	3.2	109
186	Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience. Oncologist, 2011, 16, 1292-1298.	1.9	60
187	Abstract B56: A phase 1, open-label, dose escalation, nonrandomized study to assess the maximum tolerated dose, dose limiting toxicity, and pharmacokinetics of OPB-31121 in subjects with advanced solid tumors.. , 2011, , .		1
188	This Changes Everything, Twice!. Science Translational Medicine, 2011, 3, .	5.8	0
189	Patient, Heal Thyself. Science Translational Medicine, 2011, 3, .	5.8	0
190	A Fountain of Cancer. Science Translational Medicine, 2011, 3, .	5.8	0
191	A Hair-Raising Finding in Leukemia. Science Translational Medicine, 2011, 3, .	5.8	0
192	Old Dogs and New Tricks. Science Translational Medicine, 2011, 3, .	5.8	0
193	A Death by a Thousand Cuts. Science Translational Medicine, 2011, 3, .	5.8	0
194	A Picture Is Worth a Thousand Dollars?. Science Translational Medicine, 2011, 3, .	5.8	0
195	Good Ideas Come in Small Packages. Science Translational Medicine, 2011, 3, .	5.8	0
196	The Great Escape. Science Translational Medicine, 2011, 3, .	5.8	0
197	Putting Out the Fire. Science Translational Medicine, 2011, 3, .	5.8	0
198	Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administrationâ€™ Approved Treatment. Clinical Cancer Research, 2010, 16, 4031-4037.	3.2	15

#	ARTICLE	IF	CITATIONS
199	Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse. <i>Clinical Cancer Research</i> , 2010, 16, 1289-1297.	3.2	114
200	Abstract 2687: Development of a new, highly sensitive assay for circulating tumor cell (CTC) detection based on the CellSearch [®] CTC Profile Kit enrichment and laser scanning cytometry analysis. <i>Cancer Research</i> , 2010, 70, 2687-2687.	0.4	1
201	Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies. <i>Clinical Cancer Research</i> , 2009, 15, 7061-7068.	3.2	78
202	Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4423-4432.	1.8	32
203	Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 3557-3565.	0.8	258
204	Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1001-1006.	1.9	51
205	Multiple Squamous Cell Carcinomas of the Skin After Therapy With Sorafenib Combined With Tipifarnib. <i>Archives of Dermatology</i> , 2008, 144, 779-82.	1.7	50
206	Interleukin α 6 and its receptor in cancer. <i>Cancer</i> , 2007, 110, 1911-1928.	2.0	356
207	Inhibition of Src Expression and Activity Inhibits Tumor Progression and Metastasis of Human Pancreatic Adenocarcinoma Cells in an Orthotopic Nude Mouse Model. <i>American Journal of Pathology</i> , 2006, 168, 962-972.	1.9	186
208	Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. <i>Cancer</i> , 2006, 107, 1383-1390.	2.0	76
209	Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. <i>Cancer</i> , 2005, 104, 1620-1626.	2.0	80